EVENT-DRIVEN STUDIES AND SERIOUS CHRONIC DISEASES: ADDRESSING PLACEBO, DRUG EFFICACY, AND TREATMENT FAILURE IN PULMONARY ARTERY HYPERTENSION

EVENT-DRIVEN STUDIES AND SERIOUS CHRONIC DISEASES: ADDRESSING PLACEBO, DRUG EFFICACY, AND TREATMENT FAILURE IN PULMONARY ARTERY HYPERTENSION

Clinical development of novel therapies for pulmonary artery hypertension (PAH) requires trials of larger patient cohorts, who are studied for longer periods and with more robust and meaningful efficacy endpoints, using event-driven studies. When employing an event-driven methodology in orphan condi...

Full description

Bibliographic Details
Main Authors: Henning Gall, Paul Corris
Format: Article
Language:English
Published: European Medical Journal 2014-10-01
Series:European Medical Journal Respiratory
Subjects:
event-driven study
pulmonary artery hypertension
study endpoints
biomarkers
composite endpoint
surrogate endpoint
combination therapy
sequential therapy
Online Access:https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/EVENT-DRIVEN-STUDIES-AND-SERIOUS-CHRONIC-DISEASES-ADDRESSING-PLACEBO-DRUG-EFFICACY-AND-TREATMENT-FAILURE-IN-PULMONARY-ARTERY-HYPERTENSION.pdf

Internet

https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/EVENT-DRIVEN-STUDIES-AND-SERIOUS-CHRONIC-DISEASES-ADDRESSING-PLACEBO-DRUG-EFFICACY-AND-TREATMENT-FAILURE-IN-PULMONARY-ARTERY-HYPERTENSION.pdf

Similar Items